Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications

NCT05098132 is registered in ClinicalTrials.gov with Synthekine as lead sponsor.

NCT NCT05098132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05098132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications
Lead sponsor
Synthekine
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 25, 2022
Completion date
January 31, 2029
Enrollment
364 (estimated)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

1st line nsclc, advanced solid tumor, non small cell lung cancer, untreated advanced nsclc